Book Reviews: Updates on four pediatric-related texts

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.